Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy

Vincent T. Ma, Christopher D. Lao, Leslie A. Fecher, Elena Schiopu

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Immune-related adverse events (irAEs) are a major concern when treating cancer patients with immune checkpoint inhibitor (ICI) therapy. Selecting the most appropriate management of irAEs remains an ongoing challenge because prolonged use of glucocorticoids come with their own side effects and may counteract the antineoplastic effects from immunotherapy. In this case report, we present two patients with metastatic melanoma who developed symptoms of inflammatory arthritis attributed to ICI therapy. We found that treatment with secukinumab, an anti-IL-17A inhibitor, effectively managed their symptoms and did not lead to tumor progression. Our study suggests that secukinumab can be a safe and effective treatment option for ICI-induced inflammatory arthropathy.

Original languageEnglish (US)
Pages (from-to)593-598
Number of pages6
JournalImmunotherapy
Volume14
Issue number8
DOIs
StatePublished - Jun 2022
Externally publishedYes

Keywords

  • IL-17
  • IL-17A inhibitor
  • immune-related adverse events
  • inflammatory arthritis
  • melanoma
  • psoriasis
  • psoriatic arthritis
  • secukinumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint

Dive into the research topics of 'Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy'. Together they form a unique fingerprint.

Cite this